IPO - INOVIO PHARMACEUTICALS, INC.

Form Type: 424B5

Filing Date: 2025-07-02

Corporate Action: Ipo

Type: New

Accession Number: 000119312525154972

Filing Summary: On July 2, 2025, Inovio Pharmaceuticals, Inc. filed a preliminary prospectus supplement relating to the offering of shares of common stock and warrants. The offering includes pre-funded warrants to purchase shares of common stock and accompanying Series A and Series B warrants. Each share of common stock, or its pre-funded counterpart, will be sold in fixed combinations with the warrants. The Series A warrants expire either 30 days following an announcement of FDA acceptance of a Biologic License Application for INO-3107 or 12 months from issuance, while Series B warrants expire in five years. The document outlines the offering price, underwriting discounts, and risks associated with investing in their securities, as well as the development of their clinical pipeline, particularly the BLA submission for INO-3107. The company operates within the biotechnology industry and focuses on DNA medicines for treating HPV-related diseases and other conditions. Risks highlighted include significant net losses, limited revenue sources, and dependency on regulatory approvals.